Jasper Therapeutics, Avrobio Team Up to Assess JSP191

Jasper Therapeutics, Avrobio Team Up to Assess JSP191

313954

Jasper Therapeutics, Avrobio Team Up to Assess JSP191

Jasper Therapeutics and Avrobio have entered into a non-exclusive research collaboration to evaluate the use of JSP191 in patients with Fabry disease who are being treated with one of Avrobio’s investigational gene therapies. Under this collaboration, JSP191 — an anti-CD117 monoclonal antibody — also will be evaluated in Gaucher disease type 1, another disease that is caused by lysosomal enzyme mutations, for which Avrobio is developing a gene therapy treatment. “This collaboration with Avrobio further…

You must be logged in to read/download the full post.